Form 8-K - Current report:
SEC Accession No. 0001193125-24-196481
Filing Date
2024-08-08
Accepted
2024-08-08 07:29:01
Documents
15
Period of Report
2024-08-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d862724d8k.htm   iXBRL 8-K 28202
2 EX-4.1 d862724dex41.htm EX-4.1 26385
  Complete submission text file 0001193125-24-196481.txt   222578

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20240807.xsd EX-101.SCH 4190
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20240807_def.xml EX-101.DEF 13767
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20240807_lab.xml EX-101.LAB 22888
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20240807_pre.xml EX-101.PRE 14735
17 EXTRACTED XBRL INSTANCE DOCUMENT d862724d8k_htm.xml XML 5957
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 241186054
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)